By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Retrophin, Inc. 

777 Third Avenue
22nd Floor
New York  New York  10017  U.S.A.
Phone: 646-564–3680 Fax:



Company News
Retrophin (RTRX) To Report Second Quarter 2016 Financial Results 7/22/2016 7:56:26 AM
Retrophin (RTRX) Appoints Roy D. Baynes, M.D., Ph.D., To Board Of Directors 7/20/2016 10:30:49 AM
Retrophin (RTRX) Announces New Data From Physician-Initiated Treatment With RE-024 At The 20th International Congress Of Parkinson’s Disease And Movement Disorders 6/23/2016 7:59:56 AM
Retrophin (RTRX) Pays Up to $24 Million for Rights to PBC Candidate from Asklepion 6/21/2016 6:39:27 AM
Retrophin (RTRX) To Present At The Barclays Global Healthcare Conference 3/4/2016 8:04:18 AM
Retrophin (RTRX) To Present At The Cowen and Company 36th Annual Health Care Conference 2/24/2016 11:00:49 AM
Retrophin (RTRX) Receives European Orphan Drug Designation For Sparsentan For The Treatment Of Focal Segmental Glomerulosclerosis 11/16/2015 10:52:17 AM
Retrophin (RTRX) Announces Research Collaboration With The Grace Wilsey Foundation And The Warren Family Research Center For Drug Discovery And Development At University of Notre Dame 11/5/2015 11:57:57 AM
Retrophin (RTRX) To Present At The Leerink Partners 4th Annual Rare Disease Roundtable 9/17/2015 10:52:10 AM
Retrophin (RTRX) Sues Ousted CEO Martin Shkreli for $65 Million 8/17/2015 9:07:00 AM